Age-Related Macular Degeneration (ARMD) Completed Phase 1 / 2 Trials for Ranibizumab (DB01270)

Also known as: Age-related macular degeneration / Macular Degeneration / Senile macular degeneration / Macular degeneration senile / Macular degeneration (senile) of retina, unspecified

IndicationStatusPhase
DBCOND0034150 (Age-Related Macular Degeneration (ARMD))Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01115556A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)Treatment
NCT02302989Prophylactic Ranibizumab for Exudative Age-Related Macular DegenerationPrevention
NCT02118831Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGFBasic Science
NCT0117539520089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)Treatment